MELTIN MMI
Developer of bio-signal processing and biologically inspired robotics. It offers MELTz, a hand motion rehabilitation system that uses muscle electrical data to provide training tailored to the patient's movement intentions, supporting neurorehabilitation through the integration of advanced technologies. It also, offer MELTANT, a dexterous 5-finger robot hand capable of performing non-standardized tasks. Founded in…
Funding snapshot
About
Developer of bio-signal processing and biologically inspired robotics. It offers MELTz, a hand motion rehabilitation system that uses muscle electrical data to provide training tailored to the patient's movement intentions, supporting neurorehabilitation through the integration of advanced technologies. It also, offer MELTANT, a dexterous 5-finger robot hand capable of performing non-standardized tasks. Founded in 2013, headquartered in Tokyo, Japan. The company has raised $20.1M in funding at t The company operates in Life Sciences > Orthopedics, HealthTech > Assistive Tech, High Tech > Consumer Robotics. Its business models include Consumer Robotics > Healthcare > Robotic Assistance > Prosthetics, Assistive Tech > Assistive Hardware > Mobility > Prostheses, Orthopedics > Medical Devices > Therapies > Rehabilitation > Prostheti. Founded in 2013. Headquartered in Japan, Tokyo. The company has raised funding at the Series B stage. Backed by investors including Globalink, Realtech Fund, Japan Medical Device Development Organization, Mirai Creation Fund, Sumitomo Dainippon Pharma, Dai-Ichi Life, SBI Investment, Glocalink, HILL HOUSE.
Business model
Consumer Robotics > Healthcare > Robotic Assistance > Prosthetics,
Assistive Tech > Assistive Hardware > Mobility > Prostheses,
Orthopedics > Medical Devices > Therapies > Rehabilitation > Prosthetics > Brain Interface Device
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.